GSK Will Likely Need to Book Write-down on Cough Drug Failure

Dow Jones07-17 19:57

1156 GMT - GSK will likely need to take a write-down on an experimental drug for chronic cough after it stopped clinical development, J.P. Morgan analysts say in a research note. The U.K. drugmaker said it decided to terminate development of the drug for chronic cough after it delivered mixed results in a late-stage study and missed primary and secondary objectives in another trial. JPM estimated peak sales for the drug at 1.4 billion pounds, with 2031 sales forecast at 300 million pounds. GSK's recent acquisition of Nuvalent is likely to offset some of the hit from the loss of camlipixant, but shares are still expected to be under pressure, the analysts say. Shares fall 3.7%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 17, 2026 07:57 ET (11:57 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment